Gelatinous drop-like corneal dystrophy

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Gelatinous drop-like corneal dystrophy
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Corneal opacities, vision impairment
Complications	Corneal scarring, vision loss
Onset	Usually in childhood or early adulthood
Duration	Chronic
Types
Causes	Genetic mutation in the TACSTD2 gene
Risks
Diagnosis	Slit lamp examination, genetic testing
Differential diagnosis	Other corneal dystrophies
Prevention
Treatment	Corneal transplantation, phototherapeutic keratectomy
Medication
Prognosis	Variable, often progressive
Frequency	Rare
Deaths

A rare form of corneal dystrophy

Gelatinous drop-like corneal dystrophy (GDLD) is a rare corneal dystrophy characterized by the accumulation of amyloid deposits in the cornea, leading to progressive vision impairment. This condition is typically inherited in an autosomal recessive manner and is most commonly observed in certain populations, such as in Japan.

Pathophysiology

GDLD is caused by mutations in the TACSTD2 gene, which encodes a protein involved in cell adhesion and signaling. The mutation leads to the abnormal deposition of amyloid, a proteinaceous material, in the corneal stroma. These deposits appear as gelatinous, drop-like lesions on the corneal surface, which can impair vision by disrupting the normal transparency of the cornea.

Clinical Presentation

Patients with GDLD typically present in the first or second decade of life with symptoms of decreased visual acuity, photophobia, and foreign body sensation. The hallmark of the disease is the presence of multiple, elevated, gelatinous lesions on the corneal surface, which can be observed during a slit-lamp examination.

Diagnosis

The diagnosis of GDLD is primarily clinical, based on the characteristic appearance of the cornea. However, confirmation can be obtained through genetic testing for mutations in the TACSTD2 gene. Histopathological examination of corneal tissue may reveal amyloid deposits, which can be confirmed using special staining techniques such as Congo red staining.

Management

There is currently no cure for GDLD, and management focuses on alleviating symptoms and preserving vision. Treatment options include:

• Contact lenses: Specially designed contact lenses can help improve vision by providing a smooth refractive surface.
• Corneal transplantation: In advanced cases, penetrating keratoplasty or lamellar keratoplasty may be necessary to restore vision.
• Phototherapeutic keratectomy (PTK): This laser procedure can be used to remove superficial corneal lesions and improve vision.

Prognosis

The prognosis for individuals with GDLD varies. While some patients may experience stable vision with minimal intervention, others may require multiple surgical procedures over their lifetime. Early diagnosis and management are crucial to preserving vision and improving quality of life.

See also

• Corneal dystrophy
• Amyloidosis
• Autosomal recessive disorder